Longitudinal Assessment of Estimated Glomerular Filtration Rate in Apparently Healthy Adults: A Post hoc Analysis from the JUPITER Study (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)

Clinical Therapeutics

Volumn 33, Issue 6, 2011, Pages 717-725

  Vidt, Donald G ^a   Ridker, Paul M ^b   Monyak, John T ^c   Schreiber, Martin J ^a   Cressman, Michael D ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

CKD EPI equation; EGFR; MDRD equation; Serum creatinine

Indexed keywords

C REACTIVE PROTEIN; CREATININE; ROSUVASTATIN;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INTERVENTION STUDY; KIDNEY DISEASE; KIDNEY FUNCTION; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; NORMAL HUMAN; PARAMETER; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELIABILITY;

AGED; CREATININE; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SULFONAMIDES;

EID: 79959412741     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.004     Document Type: Article

References (26)

1. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann Intern Med 2003, 139:137-147. National Kidney Foundation.
2. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
3. Myers G.L., Miller W.G., Coresh J., et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006, 52:5-18. National Kidney Disease Education Program Laboratory Working Group.
4. Davies D.F., Shock N.W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950, 29:496-507.
5. Watkin D.M., Shock N.W. Agewise standard value for CIn, CPAH and TM PAH in adult males [abstract]. J Clin Invest 1955, 34:969.
6. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
7. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009, 54:810-819.
8. Ridker P.M. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292-2297. JUPITER Study Group.
9. World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects 6th Revision, 2008, Accessed January 5, 2011. http://www.wma.net/en/30publications/10policies/b3/index.html.
10. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1) June 10, 1996, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Accessed January 5, 2011. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
11. Vidt D.G., Cressman M.D., Harris S., et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52-60.
12. Shepherd J., Vidt D.G., Miller E., et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007, 107:433-443.
13. Analysis of Covariance (Quantitative Applications in the Social Sciences) 1978, Sage QASS Series, Iowa City, IA. A.R. Wildt, O.T. Ahtola (Eds.).
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(Suppl 1):S1-S266. National Kidney Foundation.
15. Coresh J., Astor B.C., McQuillan G., et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002, 39:920-929.
16. Kroll M.H., Roach N.A., Poe B., et al. Mechanism of interference with the Jaffe reaction for creatinine. Clin Chem 1987, 33:1129-1132.
17. Andreev E., Koopman M., Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?. J Intern Med 1999, 246:247-252.
18. Go A., Chertow G., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
19. Weiner D.E., Tighiouart H., Amin M.G., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004, 15:1307-1315.
20. Keith D.S., Nichols G.A., Guillon G.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
21. Matsushita K., Selvin E., Bash L.D., et al. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010, 55:648-659.
22. White S.L., Polkinghorne K.R., Atkins R.C., et al. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010, 55:660-670.
23. Shepherd J., Kastelein J.J., Bittner V., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol 2007, 2:1131-1139.
24. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
25. Tonelli M., Isles C., Craven T., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005, 112:171-178.
26. Ridker P.M., Macfadyen J., Cressman M., et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high sensitivity C reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010, 55:1266-1273.